GSK, Hansoh ADC extends survival in lung cancer study

AI Summary

GSK, in collaboration with Hansoh, announced that an antibody-drug conjugate (ADC) targeting the B7-H3 protein shows extended survival benefits in lung cancer patients. This result represents a significant advancement in cancer treatment research focused on novel drug targets.

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.